scispace - formally typeset
Open AccessJournal ArticleDOI

Overview of the European and North American studies on HPV testing in primary cervical cancer screening.

TLDR
The results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive, with large demonstration projects needed to fully evaluate this strategy.
Abstract
Several studies suggest that HPV testing is more sensitive than cytology in primary cervical screening. These studies had different designs and were reported in different ways. Individual patient data were collected for all European and North American studies in which cytology was routinely performed and HPV testing was included as an additional parallel test. More than 60,000 women were included. The sensitivity and specificity of HPV testing were compared with routine cytology, both overall and for ages <35, 35–49 and 50+. The age-specific prevalence of high risk HPV (hr-HPV) was also analysed. HPV testing was substantially more sensitive in detecting CIN2+ than cytology (96.1% vs. 53.0%) but less specific (90.7% vs. 96.3%). The sensitivity of HPV testing was similar in all studies carried out in different areas of Europe and North America, whereas the sensitivity of cytology was highly variable. HPV sensitivity was uniformly high at all ages, whereas the sensitivity of cytology was substantially better in women over the age of 50 than in younger women (79.3% vs. 59.6%). The specificity of both tests increased with age. Positivity rates for HPV testing in women without high-grade CIN were region dependent. These results support the use of HPV testing as the sole primary screening test, with cytology reserved for women who test HPV positive. Large demonstration projects are needed to fully evaluate this strategy. © 2006 Wiley-Liss, Inc.

read more

Citations
More filters
Journal ArticleDOI

Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions.

TL;DR: The APTIMA HPV Assay had similar clinical sensitivity for disease detection but higher clinical specificity than the HC2 test, which may improve patient management and reduce the cost of care.
Journal ArticleDOI

Cervical cancer screening in the 21st century: is it time to retire the PAP smear?

TL;DR: It is likely that over the next several years screening programs will begin to switch from cervical cytology-based screening programs to programs based on testing for high-risk types of human papillomavirus (HPV), and cytology provides little benefit over using HPV testing alone to screen.
Journal ArticleDOI

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

TL;DR: It is suggested that adding an HPV vaccine to Australia's current screening regimen is a potentially cost-effective way to reduce cervical cancer and the clinical interventions that are currently associated with its prevention via screening alone.
Journal ArticleDOI

Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities, and Cancer

TL;DR: Because first generation HPV vaccines only target the two most common HPV types found in cervical cancer, cervical screening programs must continue, and the relative roles of HPV vaccination in young women and HPV testing in older women will be determined over the next decades.
Journal ArticleDOI

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening

TL;DR: Given the rarity of cancers among screened women, the contribution of cytology to screening translated to earlier detection of at most five cases per million women per year.
References
More filters
Journal ArticleDOI

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.

TL;DR: The presence of HPV in virtually all cervical cancers implies the highest worldwide attributable fraction so far reported for a specific cause of any major human cancer, and the rationale for HPV testing in addition to, or even instead of, cervical cytology in routine cervical screening.
Journal ArticleDOI

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study

TL;DR: The findings suggest that attempts to exploit the association between cervical neoplasia and HPV infection to improve effectiveness of cervical screening programmes might be undermined by the limited inferences that can be drawn from the characterisation of a woman's HPV status at a single point in time, and the short lead time gained by its detection.
Journal ArticleDOI

Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study

TL;DR: Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of cervical intraepithelial neoplasia CIN 3, and all women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dysKaryosis ought to be referred only after a second positive test for high- risk human papillsomav virus at 6 months.
Journal ArticleDOI

Trends in mortality from cervical cancer in the nordic countries: association with organised screening programmes

TL;DR: Investigation of time trends in mortality from cervical cancer in Denmark, Finland, Iceland, Norway, and Sweden since the early 1950s supports the conclusion that organised screening programmes have had a major impact on the reduction in mortality in the Nordic countries.
Journal ArticleDOI

Management of women who test positive for high-risk types of human papillomavirus: The HART study

TL;DR: Comparison of the detection rate and positive predictive values of HPV assay with cytology and the best management strategy for HPV-positive women found HPV testing was more sensitive than borderline or worse cytology but less specific for detecting CIN2+.
Related Papers (5)